期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
105例急性髓系白血病p170、GSTP-1表达分析
1
作者 曾晓颖 陈佳和 +5 位作者 沈志祥 赵慧瑾 李军民 杜心圩 倪麟 胡翊群 《肿瘤》 CAS CSCD 北大核心 2001年第2期98-100,共3页
目的 分析成人急性髓系白血病 (AML)的原发性耐药蛋白p170、GSTP 1表达和疗效、预后的关系。方法 采集AML患者治疗前骨髓液 ,采用ABC AP法检测p170、GSTP 1。结果  1 10 5例初治AML中 12例 (11 4% )出现p170或GSTP 1的阳性表达。 2 ... 目的 分析成人急性髓系白血病 (AML)的原发性耐药蛋白p170、GSTP 1表达和疗效、预后的关系。方法 采集AML患者治疗前骨髓液 ,采用ABC AP法检测p170、GSTP 1。结果  1 10 5例初治AML中 12例 (11 4% )出现p170或GSTP 1的阳性表达。 2 耐药表达阳性的 12例中CR 6例 (5 0% ) ,有效率 (CR +PR) 6 6 7% ;3 12例耐药表达阳性的患者中目前 7例死亡 ,2例复发 ,从总生存曲线来看下降较快。无病生存曲线反映 18个月追踪仅剩 2 5 %左右 ,与耐药表达阴性组比较有显著性差异 (P <0 0 5 )。结论 成人AML原发性耐药的表达是治疗效果差的指标之一 。 展开更多
关键词 急性髓系白血病 P170 gstp-1 表达 预后
下载PDF
GSTP-1基因遗传变异对术后接受替莫唑胺联合放疗的脑胶质瘤患者预后的影响 被引量:4
2
作者 赵克 倪峰 刘康栋 《肿瘤防治研究》 CAS CSCD 2019年第11期982-986,共5页
目的探讨谷胱甘肽S-转移酶P-1(GSTP-1)基因遗传变异对术后接受替莫唑胺联合放疗的脑胶质瘤患者预后的影响。方法收集患者外周血进行GSTP-1基因多态性位点基因分型。收集部分患者接受化疗前的新鲜外周血单核细胞提取RNA进行GSTP-1 mRNA... 目的探讨谷胱甘肽S-转移酶P-1(GSTP-1)基因遗传变异对术后接受替莫唑胺联合放疗的脑胶质瘤患者预后的影响。方法收集患者外周血进行GSTP-1基因多态性位点基因分型。收集部分患者接受化疗前的新鲜外周血单核细胞提取RNA进行GSTP-1 mRNA表达实验。对多态性位点和其他变量进行相关性分析。结果Ile105Val位点在研究人群中的分布频率为:G/G型68.00%(119例),G/A型29.14%(51例),A/A型2.86%(5例),最小等位基因频率为0.17,该位点基因型分布频率符合Hardy-Weinberg平衡(P=0.868)。G/A+A/A型和G/G基因型患者的中位无进展生存期(PFS)分别为4.4和6.9月,差异有统计学意义(P=0.005)。G/A+A/A型和G/G基因型患者的中位总生存期(OS)分别为11.0和15.3月,差异有统计学意义(P<0.001)。G/A+A/A基因型对OS具有独立的影响意义(OR=1.68,P=0.011)。G/A+A/A基因型患者的GSTP-1 mRNA表达较G/G型高(P<0.001)。结论GSTP-1基因Ile105Val位点可能通过影响GSTP-1基因mRNA表达进而影响接受替莫唑胺联合放疗的胶质瘤患者预后。 展开更多
关键词 脑胶质瘤 gstp-1 基因多态性 预后
下载PDF
A systemic review of glutathione S-transferase P1 Ile105Val polymorphism and colorectal cancer risk 被引量:1
3
作者 Qi-Bin Song Qi Wang Wei-Guo Hu 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2014年第3期255-267,共13页
Objectives: To investigate the correlation between glutathione S-transferase P1 (GSTP1) Ilel05Val polymorphism and colorectal cancer (CRC) risk. Methods: Studies were identified to investigate the association be... Objectives: To investigate the correlation between glutathione S-transferase P1 (GSTP1) Ilel05Val polymorphism and colorectal cancer (CRC) risk. Methods: Studies were identified to investigate the association between GSTP1 Ilel05Val polymorphism and CRC risk. Systematic computerized searches of the PubMed, Chinese National Knowledge Infrastructure, WANFANG and SinoMed were performed. Summary odds ratios (OR) and 95% confidence intervals (95 % CI) were used to measure GSTP 1 Ile 105Val polymorphisms and CRC risk. Results: A total of 23 retrospective studies were included in the meta-analysis. During all studies including 6,981 cases and 8,977 controls, sample sizes ranged from 146 to 2,144. Overall, the pooled results revealed that lie 105Val polymorphism was not associated with CRC risk and confused results were found in subgroup analyses. Further meta-analyses were conducted after excluding low-quality studies. GSTP1 Ilel05Val is associated with increased risk of CRC limited in studies with matched control. There was no significant heterogeneity in all genetic comparisons, but heterogeneity existed in subgroup analyses of heterozygous and dominant comparisons. The meta-regression analyses indicated that matched controls were the significant factor influencing between-study heterogeneity in all possible influential factors including published year, ethnicity, source of control, sample size, Hardy-Weinberg equilibrium (HWE) in control and matched controls. Sensitivity analysis revealed the pooled ORs were not changed before and after removal of each single study in all genetic comparisons, indicating the robustness of the results. Conclusions: GSTP1 Ilel05Val might be associated with increased risk of CRC. However, more high- quality case-control studies should be performed to confirm the authenticity of our conclusion. 展开更多
关键词 Colorectal neoplasm glutathione S-transferase P 1 (GSTP 1 POLYMORPHISMS
下载PDF
Polymorphisms at <i>GSTM </i>1, <i>GSTP </i>1, <i>GSTT </i>1 Detoxification Genes Loci and Risk of Breast Cancer in Kazakhstan Population
4
作者 T. S. Balmukhanov A. K. Khanseitova +3 位作者 V. G. Nigmatova E. E. Ashirbekov Sh. Zh. Talaeva N. A. Aitkhozhina 《Advances in Breast Cancer Research》 2013年第4期114-118,共5页
Associations of null polymorphism (copy number variation) of detoxification genes GSTM1, GSTT1 and GSTP1 (at rs2495636, 105 Ile/Val) with the breast cancer (BC) were assessed in two main ethnic groups of the Republic ... Associations of null polymorphism (copy number variation) of detoxification genes GSTM1, GSTT1 and GSTP1 (at rs2495636, 105 Ile/Val) with the breast cancer (BC) were assessed in two main ethnic groups of the Republic of Kazakhstan (Kazakhs and Russians). Total number of patients was 181, and of controls 397. Statistically significant difference was observed between BC patients and healthy individuals in alleles frequency (χ2 = 4.89, р = 0.007) of GSTP1 gene at rs2495636 (105 Ile/Val) among the Kazakhs ethnic group. Difference in genotypes distribution (χ2 =5.26, р = 0.076) at this site is approximating to be statistically significant. In the Russian group, no differences were found in genotypes and alleles atrs 2495636 of GSTP1 gene between cases and controls. There was no significant difference between null polymorphism (copy number variation) of GSTM1 and GSTT1 genes among cases and controls in both ethnic groups. 展开更多
关键词 Breast Cancer Gene Polymorphism GSTM 1 GSTP 1 GSTT 1 GENES Kazakhstan
下载PDF
高级别胶质瘤患者谷胱甘肽S-转移酶P-1多态性与替莫唑胺联合放疗疗效的相关性研究 被引量:1
5
作者 苏春贺 白宏英 +5 位作者 李楠 邢媛媛 苏秋羊 赵妙妙 陈杰 杨霄鹏 《中国肿瘤》 CAS CSCD 北大核心 2021年第4期313-320,共8页
[目的]探讨高级别胶质瘤患者谷胱甘肽S-转移酶P-1(glutathione S-transferase P-1,GSTP-1)基因多态性与替莫唑胺联合放疗疗效的相关性。[方法]本研究从2012年1月至2019年12月纳入268例术后接受替莫唑胺联合放疗辅助治疗的高级别胶质瘤... [目的]探讨高级别胶质瘤患者谷胱甘肽S-转移酶P-1(glutathione S-transferase P-1,GSTP-1)基因多态性与替莫唑胺联合放疗疗效的相关性。[方法]本研究从2012年1月至2019年12月纳入268例术后接受替莫唑胺联合放疗辅助治疗的高级别胶质瘤患者。通过病例系统获取患者的基线临床资料,以及后期的电话随访获取患者的预后数据,进而分析替莫唑胺联合放疗方案的预后。在患者住院期间收集患者外周血样本进行GSTP-1多态性的基因分型,并结合基线临床资料进行相应的关联分析。此外,收集可用于mRNA表达分析的样本进行GSTP-1基因的表达分析,进而探讨该位点对GSTP-1基因mRNA表达的影响。[结果]268例患者的中位无进展生存期为7.0个月,中位总生存期为13.5个月。关联分析中只发现了位于GSTP-1基因编码区域的313A>G位点和预后显著相关。313A>G位点在研究人群中的分布频率为:AA型182例(67.9%),AG型79例(29.5%),GG型7例(2.6%),最小等位基因频率为0.17,该位点基因型分布频率符合哈迪温伯格平衡(P=0.649)。AA基因型和AG/GG基因型患者的中位无进展生存期分别为9.0个月和5.8个月,差异具有显著的统计学意义(χ^(2)=14.51,P<0.001)。总生存期方面,AA型和AG/GG基因型患者的中位总生存期分别为15.5个月和10.0个月,差异具有显著的统计学意义(χ^(2)=9.53,P=0.002)。多因素分析中,针对PFS构建的Cox模型结果表明AG/GG基因型对PFS具有独立的影响(HR=1.56,P=0.005)。mRNA分析结果表明在88例外周血单核细胞标本的mRNA表达分析中,313A>G位点AG/GG基因型患者相对于野生型的AA基因型患者,PBMC标本中GSTP-1的mRNA表达显著较高(P<0.001)。[结论]高级别胶质瘤患者接受替莫唑胺联合放疗的辅助治疗具有和既往研究类似的预后,GSTP-1基因313A>G多态性位点可能成为评估该方案预后的药物基因组因素。 展开更多
关键词 高级别胶质瘤 替莫唑胺 gstp-1 药物基因组学 预后
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部